Radiofrequency Ablation of Neuroendocrine Hepatic Metastasis

Surgical Oncology Clinics of North America

Volumn 20, Issue 2, 2011, Pages 273-279

  Gamblin, T Clark ^a   Christians, Kathleen ^a   Pappas, Sam G ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Liver cancer; Neuroendocrine cancer; Radiofrequency ablation

Indexed keywords

CYTOTOXIC AGENT; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ARTIFICIAL EMBOLISM; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LIVER RESECTION; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; POSTOPERATIVE COMPLICATION; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; STOMACH CARCINOID; THERAPY EFFECT; TUMOR LOCALIZATION; TUMOR VOLUME;

CATHETER ABLATION; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS;

EID: 79952177514     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.11.002     Document Type: Review

References (29)

1. Siperstein A.E., Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001, 25:693-696.
2. Maithel S.K., Fong Y. Hepatic ablation of neuroendocrine tumor metastases. J Surg Oncol 2009, 100(8):635-638.
3. Berber E., Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol 2008, 15(10):2757-2764.
4. Atwell T.D., Charboneau J.W., Que F.G., et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005, 28:409-421.
5. Henn A.R., Levine E.A., McNulty W., et al. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. Am J Roentgenol 2003, 181:1005-1010.
6. Modlin I.M., Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997, 79:813-829.
7. Moertel C.G. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol 1987, 5:1502-1522.
8. Ihse I., Persson B., Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995, 19:76-82.
9. Shebani K.O., Souba W.W., Finkelstein D.N., et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999, 229:815-822.
10. Capella C., Heitz P.U., Hofler H., et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995, 425:547-560.
11. Carty S.E., Jensen R.T., Norton J.A. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992, 112:1024-1031.
12. Chen H., Hardacre J.M., Uzar A., et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg 1998, 187:88-92.
13. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995, 169:36-42.
14. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003, 197:29-37.
15. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000, 190:432-445.
16. Knechtle S.J., Kalayoglu M., D'Alessandro A.M., et al. Proceed with caution: liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997, 225:345-346.
17. Proye C. Natural history of liver metastasis of gastrenteropancreatic tract carcinoid tumors: place for chemoembolization. World J Surg 2001, 25:685-688.
18. Brown K.T., Koh B.Y., Brody L.A., et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999, 10:397-403.
19. Janson E.T., Westlin J.E., Eriksson B., et al. In111 octreotide scintigraphy in patients with carcinoid tumours: the predictive value of somatostatin analogue treatment. Eur J Endocrinol 1994, 131:577-581.
20. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001, 12(Suppl 2):S111-S114.
21. Rinke A., Muller H.H., Schade-Brittinger C., et al. Placebo-controlled, double blind, prospective, randomized study on the effect of octreotide in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009, 27(28):4656-4663.
22. Bajetta E., Ferrari L., Procopio G., et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002, 13:614-621.
23. Bowles B.J., Machi J., Limm W.M., et al. Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg 2001, 136:864-869.
24. Curley S.A., Izzo F., Delrio P., et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999, 230:1-8.
25. Gillams A.R. Liver ablation therapy. Br J Radiol 2004, 77:713-723.
26. Berber E., Fleshner N., Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002, 26:985-990.
27. Hellman P., Ladjevardi S., Skogseid B., et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002, 26:1052-1056.
28. Mazzaglia P.J., Berber E., Siperstein A.E. Radiofrequency thermal ablation of metastatic neuroendocrine tumors in the liver. Curr Treat Options Oncol 2007, 8:322-330.
29. Poon R.T., Ng K.K., Lam C.M., et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 2004, 239:441-449.